基因毒性杂质的控制策略及其在HPLC-MS中的应用
Control Strategies for Genotoxic Impurities and Their Application in HPLC-MS
DOI: 10.12677/HJMCe.2022.103025, PDF,   
作者: 胡克荣*, 黄 静#：贵州医科大学药学院，贵州 贵阳；陈 瑞, 班玉娟：贵州省化学合成药物研发利用工程技术研究中心，贵州 贵阳
关键词: 基因毒性杂质；HPLC-MS；警示结构；限度控制；Genotoxic Impurities； HPLC-MS； Alert Structure； Limit Control
摘要: 在药品研发中，基因毒性杂质的评估一直是药品质量评价的重点内容，关系到药品上市的安全性。基因毒性杂质危险系数高，对人体的危害性大，选用高灵敏度、专属性良好的分析仪器并结合TTC概念选择合适的分析方法是目前控制药物中基因毒性杂质含量的核心内容。其是药物开发的重要组成部分，贯穿于整个研发过程。高效液相色谱–质谱联用技术作为药物基因毒性杂质研究的有力分析工具之一，已广泛应用于多种基因毒性杂质的分析与鉴定。本文将从基因毒性杂质的概念、国内外的法规要求、以及HPLC-MS在基因毒性杂质中的应用进行概述，以期为基因毒性杂质的有效控制提供参考依据，保证患者用药安全。
Abstract: In drug research and development, the evaluation of genotoxic impurities has always been the focus of drug quality evaluation, which is related to the safety of drug marketing. Genotoxic impurities have a high risk factor and are harmful to the human body. The selection of analytical instruments with high sensitivity and good specificity and the selection of appropriate analytical methods combined with the concept of TTC are the core content of controlling the content of genotoxic impurities in drugs. It is an important part of drug development and runs through the entire R&D process. High performance liquid chromatography-mass spectrometry, as one of the powerful analytical tools for the study of drug genotoxic impurities, has been widely used in the analysis and identification of various genotoxic impurities. This article will summarize the concept of genotoxic impurities, domestic and foreign regulatory requirements, and the application of HPLC-MS in genotoxic impuri-ties, in order to provide a reference for the effective control of genotoxic impurities and ensure drug safety for patients.
文章引用：胡克荣, 陈瑞, 班玉娟, 黄静. 基因毒性杂质的控制策略及其在HPLC-MS中的应用[J]. 药物化学, 2022, 10(3): 247-256. https://doi.org/10.12677/HJMCe.2022.103025

参考文献

[1] Kątny, M. and Frankowski, M. (2017) Impurities in Drug Products and Active Pharmaceutical Ingredients. Critical Re-views in Analytical Chemistry, 47, 187-193. [Google Scholar] [CrossRef] [PubMed]
[2] Gillette, M., Taylor, A., Butulija, D., Kadiyala, H. and Jneid, H. (2020) Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare. Cardiovascular Drugs and Therapy, 34, 579-584. [Google Scholar] [CrossRef] [PubMed]
[3] Ashbyj, T.W. (1991) Definitive Relationships among Chemical Structure, Carcinogenicity and Mutagenicity for 301 Chemicals Tested by the U.S. NTP. Mutation Research, 257, 229-306. [Google Scholar] [CrossRef] [PubMed]
[4] Charoo, N.A., Ali, A.A., Buha, S.K. and Rahman, Z. (2019) Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities. AAPS PharmSciTech, 20, Article No. 166. [Google Scholar] [CrossRef] [PubMed]
[5] Reddy, A.V., Jaafar, J., Umar, K., Majid, Z.A., Aris, A.B., Talib, J., et al. (2015) Identification, Control Strategies, and Analytical Approaches for the Determination of Potential Genotoxic Impurities in Pharmaceuticals: A Comprehensive Review. Journal of Separation Science, 38, 764-779. [Google Scholar] [CrossRef] [PubMed]
[6] 王先龙. HPLC-MS联用技术在药物杂质分析中的应用[J]. 化工设计通讯, 2021, 47(7): 197-198.
[7] Bharate, S.S. (2021) Critical Analysis of Drug Product Recalls due to Nitrosa-mine Impurities. Journal of Medicinal Chemistry, 64, 2923-2936. [Google Scholar] [CrossRef] [PubMed]
[8] International Conference on Harmonization (ICH) (2017) M7(R1). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Car-cinogenic Risk.
[9] European Medicines Agency (2019) EMA Temporary Interim Limits for NMBA, DIPNA and EIPNA Impurities in Sartan Blood Pressure Medicines, EMA/351053/2019.
[10] U.S. Food and Drug Administration (FDA) (1995) Food Additives: Threshold of Regulation for Substances Used in food-Contact Articles (Final Rule). Federal Register, 60, 36582-36596.
[11] 国家药品监督管理局药品审评中心. 化学药物中亚硝胺类杂质研究技术指导原则(试行) [S]. 北京: 国家药品监督管理局, 2020.
[12] 文海若, 闫明, 王亚楠, 王翀, 耿兴超, 朱炯, 等. 药物杂质遗传毒性评价策略与监管研究[J]. 中国药事, 2020, 34(2): 131-140.
[13] Ashby, J. and Tennant, R.W. (1988) Chemical Structure, Salmonella mutagenicity and Exten of Carcinogenicity as Indicators of Genotoxic Carcino-genesis among 222 Chemicals Tested in Rodents by the US NCI/NTP. Mutation Research, 204, 17-115. [Google Scholar] [CrossRef] [PubMed]
[14] Amberg, A., Anger, L.T., Bercu, J., Bower, D., Cross, K.P., Custer, L., et al. (2019) Extending (Q)SARs to Incorporate Proprietary Knowledge for Regulatory Purposes: Is Aromatic N-Oxide a Structural Alert for Predicting DNA-Reactive Mutagenicity. Mutagenesis, 34, 67-82. [Google Scholar] [CrossRef] [PubMed]
[15] Mahony, C., Bowtell, P., Huber, M., Kosemund, K., Pfuhler, S., Zhu, T., et al. (2020) Threshold of Toxicological Concern (TTC) for Botanicals - Concentration Data Analysis of Potentially Genotoxic Constituents to Substantiate and Extend the TTC Approach to Botanicals. Food and Chemical Toxicology, 138, Article ID: 111182. [Google Scholar] [CrossRef] [PubMed]
[16] Chinese Pharmacopoeia Commission (2019) Methods for the De-tection of Sulfonate Alkyl Ester Impurities in Sulfonate Drugs (Draft).
[17] International Conference on Harmonization (ICH) (2006) Q3A(R2): Impurities in New Drug Substances.
[18] International Conference on Harmonization (ICH) (2006) Q3B(R2): Impurities in New Products.
[19] Khorolskiy, M., Ramenskaya, G., Vlasov, A., Perederyaev, O. and Maslennikova, N. (2021) Development and Validation of four Nitrosamine Impurities Determination Method in Medi-cines of Valsartan, Losartan, and Irbesartan with HPLC-MS/MS (APCI). Iranian Journal of Pharmaceutical Research, 20, 541-552.
[20] 袁松, 冯玉飞, 于颖洁, 黄海伟, 丁建. UPLC-MS/MS法测定奥美沙坦酯中7个亚硝胺类基因毒性杂质[J]. 药物评价研究2021, 44(2): 356-361.
[21] 孙兰天, 王业明, 闫红. 替格瑞洛的合成工艺优化[J]. 中国医药工业杂志, 2018, 49(4): 445-449.
[22] 骆美玉, 隽海龙. LC-MS/MS法测定盐酸吉西他滨中磺酸酯类基因毒杂质[J]. 哈尔滨商业大学学报(自然科学版), 2018, 34(3): 285-287.
[23] 曹琳, 罗淑青, 章燕, 陈军, 孙春业, 赖丛芳, 钱江. LC-QQQ-MS/MS分析苯磺酸氨氯地平中痕量苯磺酸酯类基因毒性杂质[J]. 中国现代应用药学, 2020, 37(11): 1296-1300.
[24] 易大为, 邹宇, 赵晓东, 张亚杰. GC-MS法测定甲磺酸培氟沙星中甲磺酸酯杂质的研究[J]. 中国抗生素杂志, 2017, 42(6): 521-525.
[25] Lakshmp, K.J., Devi, P.R. and Mukkanti, K. (2010) Quantita-tive Determination of Residual Hydrazine Content in Cilazapril Byion Chromato-Graph. Oriental Journal of Chemistry, 26, 1001-1006.
[26] 冯蕊, 陈冠军, 汪生. LC-MS法测定塞来昔布中2个苯肼类基因毒性杂质[J]. 中国新药杂志, 2021, 30(2): 182-186.
[27] Iliou, K., Malenović, A., Loukas, Y.L. and Dotsikas, Y. (2018) Analysis of Potential Geno-toxic Impurities in Rabeprazole Active Pharmaceutical Ingredient via Liquid Chromatography-Tandem Mass Spectrome-try, Following Quality-by-Design Principles for Method Development. Journal of Pharmaceutical and Biomedical Analysis, 149, 410-418. [Google Scholar] [CrossRef] [PubMed]
[28] Al-Sabti, B. and Harbali, J. (2021) De-velopment and Validation of an Analytical Method for Quantitative Determination of Three Potentially Genotoxic Impuri-ties in Vildagliptin Drug Material Using HPLC-MS. Journal of Separation Science, 44, 2587-2595. [Google Scholar] [CrossRef] [PubMed]
[29] 李锐, 徐金梅, 孙卫东, 邬向东. 高效液相色谱-四极杆/线性离子阱质谱法同时测定艾司奥美拉唑钠中2种潜在基因毒性杂质残留[J]. 分析测试学报, 2019, 38(4): 449-454.
[30] Al Saeedy, M., Al-Adhreai, A., Öncü-Kaya, E.M. and Şener, E. (2022) An Overview of Advances in the Chromatography of Drugs Impurity Profiling. Critical Reviews in Analytical Chemistry, 18, 1-17.
[31] 谢含仪, 林云良, 张瑞凌, 王珊珊, 陈相峰. 基因毒性杂质分析方法和前处理技术的研究进展[J]. 药物分析杂志, 2018, 38(10): 1668-1676.
[32] Udutha, S., Shankar, G., Borkar, R.M., Kumar, K., Srinivasulu, G., Guntuku, L., et al. (2018) Identifi-cation and Characterization of Stress Degradation Products of Sumatriptan Succinate by Using LC/Q-TOF-ESI-MS/MS and NMR: Toxicity Evaluation of Degradation Products. Journal of Mass Spectrometry, 53, 963-975. [Google Scholar] [CrossRef] [PubMed]